Arrowstreet Capital
RVMD icon

Arrowstreet Capital’s Revolution Medicines RVMD Stock Holding History

Arrowstreet Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,500
Closed -$1.13M – 2487
2020
Q4 		$1.13M Buy
+28,500
New +$1.13M ﹤0.01% 1791

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Arrowstreet Capital's RVMD Position: Q1 2021 in Review

Arrowstreet Capital sold out of Revolution Medicines (RVMD) in Q1 2021, closing a stake of 28,500 shares — an estimated $1.13M sold.

Arrowstreet Capital first reported a position in RVMD in Q4 2020 and held it in 1 quarter. The position peaked at $1.13M in Q4 2020. 128 funds tracked by Wall St. Rank hold RVMD as of Q1 2021.

  • Arrowstreet Capital reported no remaining Revolution Medicines position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 28,500 Revolution Medicines shares in Q1 2021, an estimated $1.13M.
  • Arrowstreet Capital first reported a position in Revolution Medicines in Q4 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Revolution Medicines position peaked at $1.13M in Q4 2020.
  • 128 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.